Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study

Next Previous
Search
Trial Profile

Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
  • Indications Adrenocortical carcinoma; Carcinoid tumour; Carcinoma; Lung cancer; Malignant thymoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms CABATEN

    • Most Recent Events

    • 04 Jun 2024 Results of a subgroup analysis of efficacy for NENs, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 27 Jan 2024 Results assessing activity and safety of cabozantinib plus atezolizumab in advanced/metastatic adrenocortical carcinoma presented at the 2024 Genitourinary Cancers Symposium
    • 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top